{"id":"lx211","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Limited public information is available regarding LX211's specific molecular mechanism. As a phase 3 candidate, it has progressed through early-stage development, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases or literature.","oneSentence":"LX211 is an investigational therapeutic in phase 3 development by Lux Biosciences with an undisclosed mechanism of action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:49:42.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01243983","phase":"PHASE3","title":"Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis","status":"COMPLETED","sponsor":"Lux Biosciences, Inc.","startDate":"2011-02","conditions":"Noninfectious Uveitis","enrollment":155},{"nctId":"NCT00404612","phase":"PHASE3","title":"A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis","status":"COMPLETED","sponsor":"Lux Biosciences, Inc.","startDate":"2007-01","conditions":"Uveitis, Posterior, Uveitis, Intermediate, Panuveitis","enrollment":218},{"nctId":"NCT00404885","phase":"PHASE3","title":"A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis","status":"COMPLETED","sponsor":"Lux Biosciences, Inc.","startDate":"2007-01","conditions":"Uveitis, Anterior, Panuveitis","enrollment":108},{"nctId":"NCT00404742","phase":"PHASE3","title":"A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis","status":"COMPLETED","sponsor":"Lux Biosciences, Inc.","startDate":"2007-01","conditions":"Uveitis, Posterior, Uveitis, Intermediate, Panuveitis","enrollment":232}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LX211","genericName":"LX211","companyName":"Lux Biosciences, Inc.","companyId":"lux-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}